Last reviewed · How we verify
NCT05489250: PLATON
The PLATON Network
trial in Hepatocellular Cancer in 565 participants. Terminated before completion.
30 June 2025
Quick facts
| Lead sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 565 |
| Start date | 28 October 2020 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 31 locations across Germany |
Conditions studied
- Hepatocellular Cancer — all drugs for Hepatocellular Cancer →
- Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
- Gallbladder Cancer — all drugs for Gallbladder Cancer →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — full company profile →
Who can join
18 and older, any sex, with Hepatocellular Cancer or Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The PLATON Network study is designed to elevate personalized therapy based on genomic tumor profiles in gastrointestinal cancer patients. Hereby, PLATON's study-design focuses on the patient's tumor molecular profiling. Within the network a web application will be developed to link clinical investigators and information on study sites, cancer patients and genetic alteration data, as well as available clinical trials at PLATON's study sites.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05489250
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Cancer
Currently open trials in the same condition.
- NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
- NCT06362369 — A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy · Phase 1, PHASE2 · recruiting
- NCT05451043 — Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabili · Phase 2 · recruiting
- NCT05701488 — SIRT With Tremelimumab and Durvalumab for Resectable HCC · Phase 1 · recruiting
- NCT05185505 — Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria · Phase 4 · recruiting
Other Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trials
Trials by the same sponsor.
- NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
- NCT07365930 — NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy · recruiting
- NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
- NCT06731803 — Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Re · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05489250 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Last refreshed: 5 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05489250.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing